<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="80115"><DrugName>epoetin beta follow-on biologic, CinnaGen</DrugName><DrugNamesKey><Name id="42988085">CinnaPoietin</Name><Name id="42861773">epoetin beta</Name></DrugNamesKey><DrugSynonyms><Name><Value>epoetin beta</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>CinnaPoietin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Betapoietin</Value></Name><Name><Value>epoetin beta follow-on biologic, CinnaGen</Value></Name></DrugSynonyms><CompanyOriginator id="1071702">CinnaGen Co</CompanyOriginator><CompaniesPrimary><Company id="1071702">CinnaGen Co</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1071702" type="Company"><TargetEntity id="4297388815" type="organizationId">CinnaGen Co</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"/><TargetEntity id="D000740" type="MeSH"/><TargetEntity id="-201701473" type="omicsDisease"/><TargetEntity id="988" type="siCondition"/></SourceEntity><SourceEntity id="PTGT-03045" type="ciTarget"><TargetEntity id="92553377420563" type="siTarget">Erythropoietin</TargetEntity><TargetEntity id="245" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Anemia - Iran - Dec-2010</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="17">Anemia</Indication></IndicationsPrimary><ActionsPrimary><Action id="12162">Erythropoietin ligand</Action></ActionsPrimary><ActionsSecondary><Action id="610">Hematopoietic stimulator</Action></ActionsSecondary><Technologies><Technology id="85">Protein recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="74">Glycoprotein</Technology><Technology id="961">Follow on biological product</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><LastModificationDate>2013-12-12T05:56:11.000Z</LastModificationDate><ChangeDateLast>2016-06-15T00:00:00.000Z</ChangeDateLast><AddedDate>2012-08-31T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1071702"&gt;CinnaGen&lt;/ulink&gt; has developed and launched CinnaPoietin (presumed to be Betapoietin), a follow-on biologic version of the recombinant human erythropoietin  &lt;ulink linkType="Drug" linkID="8121"&gt;epoetin beta&lt;/ulink&gt; (rhEPO beta), presumably for the treatment of anemia associated with chronic renal failure. By December 2010, the product had been launched in Iran [&lt;ulink linkType="Reference" linkID="1310843"&gt;1310843&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By December 2008, a clinical trial has been initiated [&lt;ulink linkType="Reference" linkID="1310843"&gt;1310843&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By December 2005, CinnaGen had begun production of rhEPO beta [&lt;ulink linkType="Reference" linkID="1310843"&gt;1310843&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1071702">CinnaGen Co</Company><Country id="IR">Iran</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1310843" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1071702">CinnaGen Co</Company><Country id="IR">Iran</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="1310843" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1071702">CinnaGen Co</Company><Country id="IR">Iran</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2008-12-31T00:00:00.000Z</StatusDate><Source id="1310843" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-03045"><Name>Erythropoietin ligand</Name><SwissprotNumbers><Swissprot>P01588</Swissprot><Swissprot>P07321</Swissprot><Swissprot>P07865</Swissprot><Swissprot>P29676</Swissprot><Swissprot>P33707</Swissprot><Swissprot>P33708</Swissprot><Swissprot>P33709</Swissprot><Swissprot>P48617</Swissprot><Swissprot>P49157</Swissprot><Swissprot>Q28513</Swissprot><Swissprot>Q867B1</Swissprot><Swissprot>Q9GKA2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1507487" linkType="reference" linkID="1507487"&gt;1507487&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>